精神病学药物基因组学:来自亚洲视角的实践建议(2024)。

IF 2.5 Q1 MEDICINE, GENERAL & INTERNAL Annals of the Academy of Medicine, Singapore Pub Date : 2024-12-26 DOI:10.47102/annals-acadmedsg.2024217
Shih Ee Goh, Saumya Shekhar Jamuar, Siew Eng Chua, Derrick Chen Kuan Yeo, Jerome Hern Yee Goh, Chee Hon Chin, Mohamed Zakir Karuvetil, Ee Lian Lee, Daniel Shuen Sheng Fung, Giles Ming Yee Tan
{"title":"精神病学药物基因组学:来自亚洲视角的实践建议(2024)。","authors":"Shih Ee Goh, Saumya Shekhar Jamuar, Siew Eng Chua, Derrick Chen Kuan Yeo, Jerome Hern Yee Goh, Chee Hon Chin, Mohamed Zakir Karuvetil, Ee Lian Lee, Daniel Shuen Sheng Fung, Giles Ming Yee Tan","doi":"10.47102/annals-acadmedsg.2024217","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacogenomic testing in psychiatry is an emerging area with potential clinical application of guiding medication choice and dosing. Interest has been fanned by commercial pharmacogenomic providers who have commonly marketed combinatorial panels that are direct-to-consumer. However, this has not been adopted widely due to a combination of barriers that include a varying evidence base, clinician and patient familiarity and acceptance, uncertainty about cost-effectiveness, and regulatory requirements. This review aims to examine recent updates in this field and provide a contextualised summary and recom-mendations for Asian populations in order to guide healthcare professionals in psychiatric practice.</p><p><strong>Method: </strong>A review of recent literature about current evidence and guidelines surrounding pharmacoge-nomics in psychiatric practice was carried out with particular attention paid to literature evaluating Asian populations. The Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework was applied. Consensus meetings comprising workgroup psychiatrists from the public and private sectors were held prior to arriving at the key recommendations.</p><p><strong>Results: </strong>Pharmacogenomic testing should be mainly limited to drug-gene pairs with established clinical evidence, such as antidepressants and <i>CYP2C19/ CYP2D6</i>. Direct-to-consumer pharmacogenomic panels that assay multiple genes and analyse them via proprietary algorithms, are not presently recommended in Singapore's psychiatric setting due to inconclusive evidence on clinical outcomes.</p><p><strong>Conclusion: </strong>Pharmacogenomic testing in psychiatry is not recommended as standard clinical practice. Exceptions may include concerns about drug concentrations or potential severe adverse drug reactions. Studies investigating newly identified drug-gene associations, and clinical effectiveness and cost-effectiveness of utilising pharmacogenomic testing in psychiatry is encouraged.</p>","PeriodicalId":502093,"journal":{"name":"Annals of the Academy of Medicine, Singapore","volume":"53 12","pages":"734-741"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024).\",\"authors\":\"Shih Ee Goh, Saumya Shekhar Jamuar, Siew Eng Chua, Derrick Chen Kuan Yeo, Jerome Hern Yee Goh, Chee Hon Chin, Mohamed Zakir Karuvetil, Ee Lian Lee, Daniel Shuen Sheng Fung, Giles Ming Yee Tan\",\"doi\":\"10.47102/annals-acadmedsg.2024217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Pharmacogenomic testing in psychiatry is an emerging area with potential clinical application of guiding medication choice and dosing. Interest has been fanned by commercial pharmacogenomic providers who have commonly marketed combinatorial panels that are direct-to-consumer. However, this has not been adopted widely due to a combination of barriers that include a varying evidence base, clinician and patient familiarity and acceptance, uncertainty about cost-effectiveness, and regulatory requirements. This review aims to examine recent updates in this field and provide a contextualised summary and recom-mendations for Asian populations in order to guide healthcare professionals in psychiatric practice.</p><p><strong>Method: </strong>A review of recent literature about current evidence and guidelines surrounding pharmacoge-nomics in psychiatric practice was carried out with particular attention paid to literature evaluating Asian populations. The Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework was applied. Consensus meetings comprising workgroup psychiatrists from the public and private sectors were held prior to arriving at the key recommendations.</p><p><strong>Results: </strong>Pharmacogenomic testing should be mainly limited to drug-gene pairs with established clinical evidence, such as antidepressants and <i>CYP2C19/ CYP2D6</i>. Direct-to-consumer pharmacogenomic panels that assay multiple genes and analyse them via proprietary algorithms, are not presently recommended in Singapore's psychiatric setting due to inconclusive evidence on clinical outcomes.</p><p><strong>Conclusion: </strong>Pharmacogenomic testing in psychiatry is not recommended as standard clinical practice. Exceptions may include concerns about drug concentrations or potential severe adverse drug reactions. Studies investigating newly identified drug-gene associations, and clinical effectiveness and cost-effectiveness of utilising pharmacogenomic testing in psychiatry is encouraged.</p>\",\"PeriodicalId\":502093,\"journal\":{\"name\":\"Annals of the Academy of Medicine, Singapore\",\"volume\":\"53 12\",\"pages\":\"734-741\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-12-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of the Academy of Medicine, Singapore\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47102/annals-acadmedsg.2024217\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the Academy of Medicine, Singapore","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47102/annals-acadmedsg.2024217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

精神病学药物基因组学检测是一个新兴领域,在指导药物选择和给药方面具有潜在的临床应用前景。商业药物基因组学提供商对其兴趣已被煽动起来,他们通常销售直接面向消费者的组合面板。然而,由于各种障碍,包括不同的证据基础、临床医生和患者的熟悉程度和接受程度、成本效益的不确定性以及监管要求,这种方法尚未被广泛采用。本综述旨在研究这一领域的最新进展,并为亚洲人群提供背景总结和建议,以指导卫生保健专业人员在精神病学实践中。方法:回顾最近关于药物经济学在精神病学实践中的证据和指南的文献,特别关注评估亚洲人群的文献。采用建议分级、评估、发展和评价证据决策框架。在达成关键建议之前,由来自公共和私营部门的精神病专家工作组组成的协商一致会议已经举行。结果:药物基因组学检测应主要局限于有临床证据的药物基因对,如抗抑郁药、CYP2C19/ CYP2D6等。由于临床结果证据不确凿,新加坡目前不推荐直接面向消费者的药物基因组学小组检测多个基因并通过专有算法进行分析。结论:精神病学药物基因组学检测不推荐作为标准临床实践。例外情况可能包括对药物浓度或潜在严重药物不良反应的担忧。鼓励研究新发现的药物-基因关联,以及在精神病学中使用药物基因组学测试的临床效果和成本效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024).

Introduction: Pharmacogenomic testing in psychiatry is an emerging area with potential clinical application of guiding medication choice and dosing. Interest has been fanned by commercial pharmacogenomic providers who have commonly marketed combinatorial panels that are direct-to-consumer. However, this has not been adopted widely due to a combination of barriers that include a varying evidence base, clinician and patient familiarity and acceptance, uncertainty about cost-effectiveness, and regulatory requirements. This review aims to examine recent updates in this field and provide a contextualised summary and recom-mendations for Asian populations in order to guide healthcare professionals in psychiatric practice.

Method: A review of recent literature about current evidence and guidelines surrounding pharmacoge-nomics in psychiatric practice was carried out with particular attention paid to literature evaluating Asian populations. The Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework was applied. Consensus meetings comprising workgroup psychiatrists from the public and private sectors were held prior to arriving at the key recommendations.

Results: Pharmacogenomic testing should be mainly limited to drug-gene pairs with established clinical evidence, such as antidepressants and CYP2C19/ CYP2D6. Direct-to-consumer pharmacogenomic panels that assay multiple genes and analyse them via proprietary algorithms, are not presently recommended in Singapore's psychiatric setting due to inconclusive evidence on clinical outcomes.

Conclusion: Pharmacogenomic testing in psychiatry is not recommended as standard clinical practice. Exceptions may include concerns about drug concentrations or potential severe adverse drug reactions. Studies investigating newly identified drug-gene associations, and clinical effectiveness and cost-effectiveness of utilising pharmacogenomic testing in psychiatry is encouraged.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Intrapleural fibrinolytic therapy: How low can we get? Knowledge, attitudes and readiness of final-year medical students towards clinical goals-of-care discussion. Perioperative emergency laparotomy pathway for patients undergoing emergency laparotomy: A propensity score matched study. Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024). COVID-19 residual symptoms and adverse drug reactions after oral antiviral therapy in the Singapore primary care setting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1